Trial results showed the "Wegovy pill" led to average weight reduction of 16.6% after 64 weeks, Novo Nordisk said.

Phase 3 trial results showed the once-weekly Cagrilintide monotherapy injection helped patients reduce their weight by 11.8% on average after 68 weeks.

Trial results showed the "Wegovy pill" led to average weight reduction of 16.6% after 64 weeks, Novo Nordisk said.

Danish drugmaker jumps by about £9bn as trial shows ‘significant weight loss’ with tablet version of Wegovy